Loading
Latest filing published 20 May 2025 for Apimeds Pharmaceuticals US, Inc.. Read the official filing
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Christopher Kim on record concern Apimeds Pharmaceuticals US, Inc. The record holds 2 filings, for trades running from 13 May 2025 to 16 May 2025.
Every open-market trade on record is a purchase: 1 purchase worth €32k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 1 share grant.
The record was last updated on 20 May 2025 with a share grant in Apimeds Pharmaceuticals US, Inc. The last purchase on record was published on 15 May 2025, which is 521 days ago. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations